DOI: https://doi.org/10.36347/sjmcr.2026.v14i10.008

Pages: 2154-2158

Introduction: The screening of CMV infection during inflammatory bowel disease (IBD) flare-ups is necessary to support the diagnosis and to carry out the therapeutic management. The objective of our work is to define the prevalence of CMV infection during IBD and to optimize the therapeutic attitude Materials and Methods: Our work is a retrospective study carried out on the whole of 5 patients of the service of gastroenterology of the HMIMV-Rabat. The diagnosis is based on the detection of anti CMV immunoglobulin, CMV pp65 antigen, viral DNA by PCR on a sample of blood or colonic mucosa and by histology and immunohistochemistry techniques during IBD exacerbations. Results: The mean age of the patients was 33,6. The sex ratio is 2F/3H. The clinical manifestations were predominantly abdominal pain, bloody stool and a rectal syndrome. The mean hemoglobin, CRP and albumin levels were 9.8g/dl; 56.2mg/l and 21.2 g/l respectively. Two of the five patients had severe lesions on endoscopy. The prevalence of CMV superinfection during IBD is calculated to be 7.7%. Ganciclovir was administered in 3 patients and two received valganciclovir Four patients were treated with combination therapy (Infliximab+Azathioprine), and one patient received Mesalazine. Conclusion: CMV superinfection during IBD is not rare, and requires specific antiviral treatment associated with the treatment of the inflammatory disease flare-up.